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Editorial
Type 2 diabetes is a pandemic and an enormous public health problem. This supplemental 
issue of Clinical Epidemiology describes the rationale, design, and implementation of 
the establishment of a large cohort of all Danes with type 2 diabetes (the DD2 study) 
and of a biobank to bridge the scientific disciplines of epidemiology, clinical medicine, 
genetics, epigenetics, and pharmacology. This will most likely result in great benefits 
for the application of evidence-based medicine to the care of, and improved outcomes 
for, Danish type 2 diabetes patients.
This real-life clinical scientific investment will be an international resource for 
diabetes research for many years to come. Type 2 diabetes is a rapidly growing disease 
affecting around 205 million people worldwide and, in a “worst case scenario”, 
439 million will be diagnosed with type 2 diabetes by the year 2025.1 The disease 
is associated with a two-fold increased mortality rate compared with the general 
population, due to complications such as myocardial infarction, stroke, gangrene in the 
lower extremities, end-stage renal failure, and blindness. The excess global mortality in 
2000 attributable to diabetes overall, most of which was attributable to type 2 diabetes, 
was 2.9 million deaths. These complications are very troublesome for the individual 
diabetic patient and major public health problem.
Therefore, cost-effective national organization and intervention are strongly needed, 
both in order to prevent the disease, but also in an attempt to improve treatment of the 
metabolic abnormalities behind the disease with the aim of preventing the devastating 
complications.
Recent clinical trials2,3 have emphasized the importance of early intensive treatment 
of type 2 diabetes patients in order to prevent complications and improve quality of 
life. Therefore, evidence for new national guidelines for treatment and organisation 
for newly diagnosed type 2 diabetes patients is needed. In this case – if the guidelines 
are effective – the prognosis of newly diagnosed patients may be expected to improve 
significantly.
The overall aim of the DD2 study is to near-normalize metabolic control in newly 
diagnosed type 2 diabetes patients in order to prevent diabetic complications and 
improve quality of life. The DD2 study thus has two specific aims:
1. To investigate whether or not it is possible through treatment guidelines and struc-
tured organization to near-normalize the risk profile and to avoid/reduce diabetic 
complications by continuous monitoring through Danish health registries, thereby 
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obtaining knowledge about predictors for the long-term 
outcome and thus objectives for new interventions.
2. To establish a biobank of DNA and plasma, urine, and 
tissue samples for individual characterization of type 2 
diabetes patients that will improve the prognosis and build 
a platform for individualized treatment.
In Denmark the outcome of treatment and clinical course 
can be followed through comprehensive health registries with 
complete follow-up.4 Therefore the DD2 study will be able 
to evaluate treatment and intervene if the current treatment 
fails. Based on the data obtained, outcome will be evaluated 
prospectively, independently of the specific phenotypes and 
genotypes, and will thus be unbiased.
The identification of new genes and pathways involved in 
type 2 diabetes predisposition and increased risk of diabetic 
complications offers opportunities for developing novel 
therapeutic and preventative approaches. Furthermore, the 
identification of additional genetic variants – both protective 
and risk variants – may render it possible to use patterns 
of predisposition to tailor individual management of these 
conditions.
Denmark holds an internationally leading position within 
many aspects of clinical care and diabetes research, but such 
Danish research has been carried out in many institutions 
focusing on different aspects such as physiology, clinical 
medicine, health services research, biotechnology, clinical 
epidemiology, and biostatistics.
The pandemic of type 2 diabetes is showing no signs of 
abatement and therefore progress is urgently needed to slow 
progression and reduce the consequences. The establishment 
of a large cohort of all Danes with type 2 diabetes and of 
a biobank to bridge all scientific disciplines will be an 
important international resource for diabetes research for 
many years.
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Table S2 Departments/outpatient clinics that have consented to participate in DD2, but have not yet referred any patients
Hospital Department Responsible consultant
Rigshospitalet Clinic of Medicine and Endocrinology Allan Vaag
Aabenraa Hospital Dept of Medicine Jolanta Topolska
Haderslev Hospital Dept of Medicine Jolanta Topolska
Esbjerg Hospital Dept of Medicine Jeppe Gram
Hospital Vendsyssel Dept of Medicine Kim Helg Christiansen
Slagelse Hospital Dept of Medicine Henning Friis Juhl
Dronninglund Hospital Center of Medicine Aalborg, Dronninglund Grzegorz Jaroslaw Pacyk
Frederiksberg hospital Clinic of Cardiology and Endocrinology E Anne Elisabeth Jarløv
Køge Hospital Dept of Medicine Leif Breum
Helsingør Hospital Dept of Medicine Per Lund / Pernille Vedel
Table S1 Hospitals participating in DD2 (June 2012)
Hospital Department Responsible consultant
Odense University Hospital Dept of Endocrinology M Henning Beck-Nielsen 
Jan-Erik Henriksen
Fredericia Hospital Dept of Medicine Hans Gjessing
NBG—Aarhus University Hospital Dept of Medicine and Endocrinology Jens Sandahl Christiansen
Svendborg Hospital Outpatient Dept of Diabete Klaus Levin
THG—Aarhus University Hospital Dept of Medicine and Endocrinology Jørgen Rungby
Regional Hospital Viborg Outpatient Dept of Endocrinology Torben Østergaard
Hospital Unit Nyborg Outpatient Dept of Endocrinology Klaus Levin
Vejle Hospital Outpatient Dept of Medicine Cramer Christensen
Herlev Hospital Dept of Medicine and Endocrinology Henrik Westergaard
Regional Hospital Silkeborg Dept of Medicine Klaus W Hansen
Regional Hospital Randers Clinic of Endocrinology C10 Henning K Nielsen
Bispebjerg Hospital IC – Research Hans Perrild
Aalborg Hospital Endocrinology Lab 2 Hospital West Hans-Henrik Lervang
Regional Hospital Horsens Dept of Medicine Lise-Lotte Fisker
Hillerød Hospital Dept of Cardiology and Endocrinology H 0652 Michael Røder
Steno Diabetes Center Steno Diabetes Center Peter Rossing
Hospital Himmerland Farsø Dept of Medicine Henning S Rønne
Sønderborg Hospital Outpatient Dept of Diabetes (M43) Hans R Rasmussen 
Regional Hospital Herning Dept of Medicine Nancy Kristensen 
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Table S3 General practitioners participating in DD2 (June 2012)
Name Address
Glamsbjerglægerne Stensgårdsvej 20, 5620 Glamsbjerg
Mogens Carl Petersen Fynsvej 7, 6000 Kolding
Lægerne Nørre Voldgade 58 Nørrevoldgade 58, 5800 Nyborg
Lægerne Willemoesvej Willemoesvej 31, 5700 Svendborg
J.Ravn and M.Richert Vestergade 2, 6640 Lunderskov
Jacobilægerne Ringkøbingvej 38, 6800 Varde
Lægerne i Oksbøl Torvegade 17, 6840 Oksbøl
Lili Tronegård-M. and Michael 
Schmidt
Birkevej 2, 5300 Kerteminde
Lægerne J B Winsløws Vej J.B. Winsløws Vej 9 A, 5000 
Odense C
Lægehuset—Farum Midtpunkt Nygårdterrasserne 204, 3520 
Farum
Lægekompagniskabet Venusvej 2 Venusvej 2, 7000 Fredericia
Paul Jørgen Schultz Aps Hovedgaden Vest 86, 6500 Vojens
Lægerne Danmarksgade 13 Danmarksgade 13, 7000 Fredericia
Haarbylægerne Møllevej 2, 5683 Hårby
Lægerne i Nr. Lyndelse Aps Carl Nielsensvej 1, 5792 Årslev
Lægerne i Østergade Østergade 1, 2., 5750 Ringe
Larsen, Glenthøj and Nielsen Birkevej 2, 5300 Kerteminde
Claus Olesen and Elin Franck Ny Vestergade 1, 1., 6000 Kolding
Lægehuset Havnepladsen Torvegade 16 A, 6800 Varde
Lægeklinikken Østergade 10 Østergade 10, St., 6500 Vojens
Lægerne i Vindeby Bregningevej 48, 5700 Svendborg
Bylægen Peer Kirkebjerg Skt. Anne Plads 2, 5000 Odense C
Lægehuset i Rødding Louisevej 13, 6630 Rødding
Peter Larsen Skt. Anne Plads 4, 1., 5000 
Odense C
Lægerne i Harndrup Skovvej 2, 5463 Harndrup
Bente K. Bertelsen Tvedgade 21, 6760 Ribe
Lægehuset Aps. Mellemgade 19 A, 5600 Faaborg
Lone Manane and Bent Stolberg Mommarkvej 259, 6470 Sydals




Bau-Madsen, Fricke and Stavenuiter Egevænget 4, 5771 Stenstrup
Dorothee Paul Vidågade 48, st. tv., 6270 Tønder
Lægerne i Bjert Gl. Bjært 26, 6091 Bjert
Peter G Petersen Murtfeldts Plads 5, 6800 Varde
Morten Toftager Birkevej 2, 5300 Kerteminde
Lægerne Vissingsgade 21 Vissingsgade 21, 7100 Vejle
Lægerne Kongensgade Kongensgade 27, 4., 5000 
Odense C
Kim Rønhof Sankt Nicolai Gade 6, st., 
5700 Svendborg
Hanne Christensen Kongensgade 3, 6070 
Christiansfeld
Lægehuset Nørre Aaby Æblehaven 1, 5580 Nørre  
Aaby
Lægerne Englandsgade 8 Englandsgade 8, 6700 Esbjerg
Marianne Bov Skt. Anne Plads 2, 1., 5000 
Odense C
Stig Gerdes Danmarksgade 11, 1. tv., 7000 
Fredericia
Carsten Winther Jakobsen Kongensgade 38, 2. th., 5000 
Odense C
Bak og Larsen Teglgårdsparken 100, 1., 5500 
Middelfart
Lægerne Vestergade Vestergade 2D, 1., 6600 Vejen
Berkjær, Iversen Bønløkke, Ellegaard Ulsnæs 4, 
6300 Gråsten 
Søndersø Lægehus Vesterled 2, 5471 Søndersø 
Annemette Als Kongevej 37, 6300 Gråsten  
Lægerne Jernbanegade Jernbanegade 4, 7000 Fredericia  
Lægerne Syrenvej 2 Syrenvej 2, 7080 Børkop  
Sundhedscenter Vejle Nordås 17K, 7100 Vejle 
Peter Mikael Klubien M D Madsensvej 9,1, 3450 Allerød  
Lægeklinikken Danmarksgade 22 Danmarksgade 22, 7500 
Holstebro
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